The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4%

during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market.

New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Application, End User - Global Forecast to 2026" - https://www.reportlinker.com/p05108757/?utm_source=GNW
However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period
The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research.The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period.

This segment’s high growth rate can be attributed to the rising number of clinical trials every year.

Contract research organizations segment accounted for the highest CAGR
Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions.During the forecast period contract research organizations accounted for the highest growth rate.

The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Rat models segment accounted for the highest CAGR
Based on type, the PDX models market is segmented into mice models and rat models.The rat models segment accounted for the highest growth rate during the forecast period.

Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.

Respiratory tumor models segment accounted for the highest CAGR
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models.The respiratory tumor models segment accounted for the highest growth rate during the forecast period.

The key factor driving this segment’s growth is the increasing incidence of lung cancers globally.

Asia Pacific: The fastest-growing country in the PDX models market
The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.Asia Pacific is projected to register the highest CAGR during the forecast period.

Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:
• JSR Corporation (Japan)
• WuXi AppTec (China)
• Champions Oncology, Inc. (US)
• THE JACKSON LABORATORY (US)
• Charles River Laboratories (US)
• Oncodesign (France)
• Envigo (US)
• Pharmatest Services (Finland)
• Hera BioLabs (US)
• EPO Berlin-Buch GmbH (Germany)
• Xentech (France)
• Urosphere (France)
• Abnova Corporation (Taiwan)
• Genesis Biotechnology Group (US)
• Explora BioLabs (US)
• Biocytogen (US)
• Living Tumor Laboratory (Canada)
• Bioduro (US)
• Aragen Life Sciences w.e.f, (US)
• Shanghai Lide Biotech Co., Ltd. (China)

Research Coverage:
This report provides a detailed picture of the PDX models market.It aims at estimating the size and future growth potential of the market across different segments, such as type, tumor type, application, end user, and region.

The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall PDX models market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.

This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Read the full report: https://www.reportlinker.com/p05108757/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001